Paradigm raises $1.5m to push global sales expansion of eye imager:
This article was originally published in Clinica
Diagnostic systems developer Paradigm Medical Industries is to ramp up its global sales and marketing efforts, using the $1.5m it raised from a recent convertible note sale. The company will focus particularly on its lead product, the P60 Ultrasound BioMicroscope (UBM), a fourth-generation ultrasound device for imaging conditions of the eye. The system is approved in the US, various European and Pacific Rim countries and, most recently, in Canada (see Clinica No 1196, p 18). The proceeds from the note sale will also go towards building up the Salt Lake City, Utah firm's inventory.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.